erlotinib hydrochloride has been researched along with quinacrine in 3 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (quinacrine) | Trials (quinacrine) | Recent Studies (post-2010) (quinacrine) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 4,051 | 65 | 289 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | quinacrine (IC50) |
|---|---|---|---|
| cystic fibrosis transmembrane conductance regulator | Homo sapiens (human) | 19.88 | |
| Major prion protein | Mus musculus (house mouse) | 0.0951 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 2.896 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.964 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 1.983 | |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 4.5 | |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 4.5 | |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 4.5 | |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 4.5 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 3.736 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 2.28 | |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 4.5 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 1.489 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 1.825 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 3.857 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 1.255 | |
| Acetylcholinesterase | Homo sapiens (human) | 2.667 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.896 | |
| Histamine H2 receptor | Homo sapiens (human) | 3.535 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 2.065 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 2.663 | |
| D(3) dopamine receptor | Homo sapiens (human) | 1.318 | |
| Aldehyde oxidase 1 | Oryctolagus cuniculus (rabbit) | 10 | |
| Cholinesterase | Equus caballus (horse) | 4.5 | |
| Aldehyde oxidase | Homo sapiens (human) | 3.3 | |
| Cyclic GMP-AMP synthase | Homo sapiens (human) | 7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| De, S; Dermawan, JK; Dowlati, A; Gurova, K; Narla, G; Pink, J; Sharma, N; Stark, GR | 1 |
| Bhateja, P; Dowlati, A; Sharma, N | 1 |
| Gupta, V; Kulkarni, NS; Vaidya, B | 1 |
1 trial(s) available for erlotinib hydrochloride and quinacrine
| Article | Year |
|---|---|
Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinacrine | 2018 |
2 other study(ies) available for erlotinib hydrochloride and quinacrine
| Article | Year |
|---|---|
Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA; DNA-Binding Proteins; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; High Mobility Group Proteins; Humans; Luciferases; Lung Neoplasms; Mice; Mice, Nude; NF-kappa B p50 Subunit; Quinacrine; Quinazolines; RNA, Small Interfering; Transcriptional Elongation Factors; Xenograft Model Antitumor Assays | 2014 |
Nano-synergistic combination of Erlotinib and Quinacrine for non-small cell lung cancer (NSCLC) therapeutics - Evaluation in biologically relevant in-vitro models.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinacrine | 2021 |